Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

N-038

Supelco

6β-Naltrexol solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing

Empirical Formula (Hill Notation):
C20H25NO4
CAS Number:
Molecular Weight:
343.42
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

OC1=C(O2)C([C@]([C@@H]2[C@H](O)CC3)(CCN4CC5CC5)[C@]3(O)[C@H]4C6)=C6C=C1

InChI

1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1

InChI key

JLVNEHKORQFVQJ-PYIJOLGTSA-N

General description

6ß-Naltrexol is the primary urinary metabolite of Naltrexone, an opiate sold under the trade names Revia, Depade, and Vivitrol® and used primarily in the management of alcohol or opiate dependence. This analytical reference standard is appropriate for use in LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Application



  • Advanced analytical techniques for pharmacokinetics: The development of a rapid and sensitive gas chromatography-mass spectrometry method for nalmefene quantification in human plasma, pivotal for pharmacokinetic studies, underscores the importance of 6β-Naltrexol in therapeutic drug monitoring and addiction treatment research (Xie et al., 2002).



Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivitrol is a registered trademark of Alkermes, Inc.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

WGK

WGK 1

Flash Point(F)

closed cup

Flash Point(C)

closed cup

Regulatory Information

危险化学品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stan L Banks et al.
Pharmaceutical research, 25(7), 1677-1685 (2008-05-02)
The purpose of this investigation was to evaluate the in vitro microneedle (MN) enhanced percutaneous absorption of naltrexone hydrochloride salt (NTX x HCl) compared to naltrexone base (NTX) in hairless guinea pig skin (GP) and human abdominal skin. In a
Waleed O Farid et al.
PloS one, 7(12), e52812-e52812 (2013-01-10)
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally administered sustained-release naltrexone on the rat brain
Ling-Di Yan et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 44(7), 722-725 (2009-10-08)
The pharmacokinetics of 6beta-naltrexol (6beta-NOL) following single intramuscular administration and multiple intramuscular injection once per day for seven days was studied in 4 Beagle dogs. Plasma concentration of 6beta-NOL in dogs was analyzed by a combination of high performance liquid
Mary F Divin et al.
European journal of pharmacology, 583(1), 48-55 (2008-02-16)
It has been proposed that on chronic morphine treatment the micro-opioid receptor becomes constitutively active, and as a consequence, the opioid withdrawal response arises from a reduction in the level of this constitutively active receptor. In support of this, the
Joi L Dunbar et al.
Journal of studies on alcohol and drugs, 68(6), 862-870 (2007-10-26)
Injectable extended-release naltrexone (XR-NTX; Vivitrol) has recently been approved for the treatment of alcohol dependence. A population pharmacokinetic (PPK) analysis examined the possibility of altered pharmacokinetics for naltrexone and its primary metabolite, 6beta-naltrexol, in subpopulations with a potential for alcohol-dependence

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service